SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Sanderling Venture Partners V, LP

(Last) (First) (Middle)
400 SOUTH EL CAMINO REAL, SUITE 1200

(Street)
SAN MATEO CA 94402

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CHIMERIX INC [ CMRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2013
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/13/2013 J(1) 94,633 D $0 4,161,193 I See Footnote(2)
Common Stock 11/13/2013 J(3) 7,543 D $0 4,153,650 I See Footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Sanderling Venture Partners V, LP

(Last) (First) (Middle)
400 SOUTH EL CAMINO REAL, SUITE 1200

(Street)
SAN MATEO CA 94402

(City) (State) (Zip)
1. Name and Address of Reporting Person*
SANDERLING V BIOMEDICAL LP

(Last) (First) (Middle)
400 SOUTH EL CAMINO REAL, SUITE 1200

(Street)
SAN MATEO CA 94402

(City) (State) (Zip)
1. Name and Address of Reporting Person*
SANDERLING V LTD PARTNERSHIP

(Last) (First) (Middle)
400 SOUTH EL CAMINO REAL, SUITE 1200

(Street)
SAN MATEO CA 94402

(City) (State) (Zip)
1. Name and Address of Reporting Person*
SANDERLING V BETEILIGUNGS GMBH & CO KG

(Last) (First) (Middle)
400 SOUTH EL CAMINO REAL, SUITE 1200

(Street)
SAN MATEO CA 94402

(City) (State) (Zip)
1. Name and Address of Reporting Person*
SANDERLING VENTURES MANAGEMENT V

(Last) (First) (Middle)
400 SOUTH EL CAMINO REAL, SUITE 1200

(Street)
SAN MATEO CA 94402

(City) (State) (Zip)
1. Name and Address of Reporting Person*
SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP

(Last) (First) (Middle)
400 SOUTH EL CAMINO REAL, SUITE 1200

(Street)
SAN MATEO CA 94402

(City) (State) (Zip)
1. Name and Address of Reporting Person*
Sanderling Venture Partners V Co Investment Fund, LP

(Last) (First) (Middle)
400 SOUTH EL CAMINO REAL, SUITE 1200

(Street)
SAN MATEO CA 94402

(City) (State) (Zip)
1. Name and Address of Reporting Person*
Sanderling V Strategic Exit Fund LP

(Last) (First) (Middle)
400 SOUTH EL CAMINO REAL, SUITE 1200

(Street)
SAN MATEO CA 94402

(City) (State) (Zip)
1. Name and Address of Reporting Person*
Sanderling Venture Partners VI Co Investment Fund LP

(Last) (First) (Middle)
400 SOUTH EL CAMINO REAL, SUITE 1200

(Street)
SAN MATEO CA 94402

(City) (State) (Zip)
1. Name and Address of Reporting Person*
Sanderling VI Beteiligungs GmbH & Co KG

(Last) (First) (Middle)
400 SOUTH EL CAMINO REAL, SUITE 1200

(Street)
SAN MATEO CA 94402

(City) (State) (Zip)
Explanation of Responses:
1. Pro rata distribution by Sanderling Ventures Management V to its Managing Directors.
2. See attached Exhibit 99.1
3. Pro rata distribution by Sanderling Ventures Management VI to its Managing Directors.
Remarks:
Form 4 filing 1 of 2. See Form 4 filing 2 of 2 for additional members of this joint filing.
See Signatures Included in Exhibit 99.2 11/15/2013
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 

Exhibit 99.1

 

 

(2) Following the pro-rata distributions reported herein, the shares of Common Stock are held as follows: 1,116,596 shares of common stock held by Sanderling Venture Partners V, L.P., 273,434 shares of common stock held by Sanderling V Biomedical, L.P., 155,143 shares of common stock held by Sanderling V Limited Partnership, 138,046 shares of common stock held by Sanderling V Beteiligungs GmbH & Co. KG, 281,053 shares of common stock held by Sanderling V Biomedical Co-Investment Fund, L.P., 463,582 shares of common stock held by Sanderling Venture Partners V Co-Investment Fund, L.P., 891,189 shares of common stock held by Sanderling V Strategic Exit Fund, L.P. (collectively, the Sanderling V Shares), 797,346 shares of common stock held by Sanderling Venture Partners VI Co-Investment Fund, L.P., 15,431 shares of common stock held by Sanderling VI Beteiligungs GmbH & Co. KG, 18,384 shares of common stock held by Sanderling VI Limited Partnership (collectively, the Sanderling VI Shares) and 3,446 shares of common stock held by Middleton-McNeil Retirement Trust. Timothy J. Wollaeger, one of the Issuer’s directors, Fred A. Middleton, Robert G. McNeil and Timothy C. Mills share voting and investment power with respect to the Sanderling V Shares. Robert G. McNeil, Fred A. Middleton, Timothy C. Mills and Timothy J. Wollaeger share voting and investment power with respect to the Sanderling VI Shares. Fred A. Middleton and Robert G. McNeil share voting and investment power with respect to the shares held by the Middleton-McNeil Retirement Trust. Each of these individuals disclaims beneficial ownership of such securities, except to the extent of his or her pecuniary interest therein.

 

 

 

 

Exhibit 99.2

 

Signature of Reporting Persons:

 

This statement on Form 4 is filed is filed by Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Ventures Management, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling Venture Partners V Co-Investment Fund, L.P., Sanderling V Strategic Exit Fund, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., and Sanderling VI Beteiligungs GmbH & Co. KG. The principal business address of each of the reporting persons is c/o Sanderling Venture Partners V, L.P., 400 South El Camino Real, Suite 1200, San Mateo, CA 94402. The reporting entities disclaim beneficial ownership of the securities listed herein except to the extent of their pecuniary interest therein.

 

Sanderling Venture Partners V, L.P.

By: Middleton, McNeil & Mills Associates V, LLC

 

By:     /s/ Timothy J. Wollaeger                                       

Timothy J. Wollaeger

Managing Director

 

Sanderling V Biomedical, L.P.

By: Middleton, McNeil & Mills Associates V, LLC

 

By:     /s/ Timothy J. Wollaeger                                       

Timothy J. Wollaeger

Managing Director

 

Sanderling V Limited Partnership

By: Middleton, McNeil & Mills Associates V, LLC

 

By:     /s/ Timothy J. Wollaeger                                       

Timothy J. Wollaeger

Managing Director

 

Sanderling V Beteiligungs GmbH & Co. KG

By: Middleton, McNeil & Mills Associates V, LLC

 

By:     /s/ Timothy J. Wollaeger                                       

Timothy J. Wollaeger

Managing Director

 

Sanderling V Ventures Management

 

 

By:     /s/ Timothy J. Wollaeger                                       

Timothy J. Wollaeger

Owner

 

Sanderling V Biomedical Co-Investment Fund, L.P.

By: Middleton, McNeil & Mills Associates V, LLC

 

By:     /s/ Timothy J. Wollaeger                                       

Timothy J. Wollaeger

Managing Director

 

Sanderling Venture Partners V Co-Investment Fund, L.P.

By: Middleton, McNeil & Mills Associates V, LLC

 

By:     /s/ Timothy J. Wollaeger                                       

Timothy J. Wollaeger

Managing Director

 

Sanderling V Strategic Exit Fund, L.P.

By: Middleton, McNeil, & Mills Associates V, LLC

 

By:     /s/ Timothy J. Wollaeger                                       

Timothy J. Wollaeger

Managing Director

 

Sanderling Venture Partners VI Co-Investment Fund, L.P.

By: Middleton, McNeil, Mills & Associates VI, LLC

 

By:     /s/ Timothy J. Wollaeger                                       

Timothy J. Wollaeger

Managing Director

 

Sanderling VI Beteiligungs GmbH & Co. KG

By: Middleton, McNeil, Mills & Associates VI, LLC

 

By:     /s/ Timothy J. Wollaeger                                       

Timothy J. Wollaeger

Managing Director